{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:13:30Z","timestamp":1778026410583,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007418","name":"Konica Minolta Science and Technology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cllc.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:15:37Z","timestamp":1773159337000},"page":"81-90.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non\u2013Small Cell Lung Cancer: A Nationwide C CAT Cohort From Japan"],"prefix":"10.1016","volume":"27","author":[{"given":"Mika","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4489-5243","authenticated-orcid":false,"given":"Takahiro","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Kage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cllc.2026.03.003_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.cllc.2026.03.003_bib0002","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cllc.2026.03.003_bib0003","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jtho.2019.01.011","article-title":"Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC)","volume":"14","author":"Jeanson","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.03.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104816","article-title":"Heterogeneous PD-L1 expression in metastases impacts immunotherapy response","volume":"97","author":"Hu","year":"2023","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.cllc.2026.03.003_bib0005","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.003_bib0006","doi-asserted-by":"crossref","first-page":"590","DOI":"10.21037\/tlcr-20-573","article-title":"Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer","volume":"10","author":"Pradhan","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.003_bib0007","article-title":"Prognostic characteristics and immunotherapy response of patients with nonsquamous NSCLC with Kras mutation in East Asian populations: a single-center cohort study in Taiwan","volume":"2","author":"Wu","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"8","key":"10.1016\/j.cllc.2026.03.003_bib0008","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jtho.2018.04.024","article-title":"BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors","volume":"13","author":"Dudnik","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2026.03.003_bib0009","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.cllc.2026.03.003_bib0010","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.03.003_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1249237","article-title":"Metabolic barriers in non-small cell lung cancer with LKB1 and\/or KEAP1 mutations for immunotherapeutic strategies","volume":"13","author":"Tanaka","year":"2023","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2026.03.003_bib0012","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.cllc.2026.03.003_bib0013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jtho.2020.11.015","article-title":"Clinical implication of KEAP1-NFE2L2 mutations in NSCLC","volume":"16","author":"Hellyer","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2026.03.003_bib0014","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: the National Datacenter for cancer genomic medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov"},{"issue":"7666","key":"10.1016\/j.cllc.2026.03.003_bib0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.003_bib0016","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/1078-0432.CCR-18-2062","article-title":"Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer","volume":"25","author":"Dagogo-Jack","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.cllc.2026.03.003_bib0017","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/cas.15651","article-title":"Selection bias due to delayed comprehensive genomic profiling in Japan","volume":"114","author":"Tamura","year":"2023","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000706","article-title":"STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort","volume":"5","author":"Papillon-Cavanagh","year":"2020","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.cllc.2026.03.003_bib0019","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jtho.2024.03.002","article-title":"Precision immunotherapy for STK11\/KEAP1-mutant NSCLC","volume":"19","author":"Ricciuti","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"7511","key":"10.1016\/j.cllc.2026.03.003_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.cllc.2026.03.003_bib0021","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and pathological characteristics of KEAP1- and NFE2L2-mutated non-small cell lung carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.cllc.2026.03.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.003_bib0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","article-title":"Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer","volume":"9","author":"Kitajima","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2026.03.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.cllc.2026.03.003_bib0025","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00262-021-03031-1","article-title":"Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials","volume":"71","author":"Landre","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.cllc.2026.03.003_bib0026","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.cllc.2026.03.003_bib0027","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"23","key":"10.1016\/j.cllc.2026.03.003_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312972","article-title":"Navigating therapeutic challenges in BRAF-mutated NSCLC: non-V600 mutations, immunotherapy, and overcoming resistance","volume":"25","author":"Bortolot","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.cllc.2026.03.003_bib0029","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","article-title":"Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma","volume":"20","author":"Atefi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.cllc.2026.03.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273207","article-title":"Various impacts of driver mutations on the PD-L1 expression of NSCLC","volume":"17","author":"Chu","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.003_bib0031","article-title":"Patients with BRAF-mutant NSCLC may not benefit from immune checkpoint inhibitors: a population-based study","volume":"1","author":"Zhang","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2026.03.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225036","article-title":"Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.003_bib0033","first-page":"77","article-title":"Treatment sequences in BRAF-V600-mutated NSCLC: first-line targeted therapy versus first-line (Chemo-) immunotherapy","volume":"20","author":"Wiesweg","year":"2025","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:55:43Z","timestamp":1778025343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1525730426000379"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.03.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non\u2013Small Cell Lung Cancer: A Nationwide CCAT Cohort From Japan","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}